Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.07, Morningstar.com reports.
Shares of Aptose Biosciences (NASDAQ:APTO) traded down 2.01% during trading on Friday, hitting $1.46. The company had a trading volume of 110,358 shares. Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $3.20. The company’s market capitalization is $35.08 million. The stock’s 50-day moving average price is $1.48 and its 200 day moving average price is $1.19.
Several research analysts have recently commented on APTO shares. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Monday, August 14th. HC Wainwright started coverage on Aptose Biosciences in a research note on Thursday, June 8th. They issued a “hold” rating for the company. ValuEngine raised Aptose Biosciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 12th. Rodman & Renshaw began coverage on Aptose Biosciences in a research note on Thursday, June 8th. They issued a “neutral” rating for the company. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, May 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $7.13.
TRADEMARK VIOLATION NOTICE: This news story was first published by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/aptose-biosciences-inc-apto-issues-quarterly-earnings-results-beats-estimates-by-0-07-eps-updated.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.